Published in Clinical Oncology Week, April 10th, 2006
Revenues for the year were $210,000, compared to $5.0 million for the year ended December 31, 2004. Revenues for the fourth quarter of 2005 were $37,000, compared to $75,000 for the same period in 2004.
The net loss for the year ended December 31, 2005 was $81.5 million, or $1.36 per share, compared to $75.2 million, or $1.32 per share for the year ended December 31, 2004. Net loss in the fourth quarter of 2005 was $24.8 million, or $0.40 per share, compared to a net loss of $21.7 million, or $0.37 per share, for the same period in 2004. Dendreon's total...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.